Baidu
map

中科院上海药物所药物化学室:新药研发坚强后盾

2016-09-15 朱熊 黄辛 中国科学报

中科院上海药物所药物化学室:新药研发坚强后盾

 

■通讯员 朱熊 本报记者 黄辛

2015年,中科院上海药物所药物化学研究室实现7个新药项目的转让,转让金额近4亿元,其中1个已获国家食品药品监督管理总局颁发的新药临床试验批件,4个新药正在审批当中。

今年七一前夕,药化党总支被授予“中科院上海分院先进基层党组织称号”。药化党总支书记张翱在接受《中国科学报》记者采访时表示,药化党总支将一如既往地围绕建设药物创新研究院、抓住研究所“出新药”战略,充分发挥好推进新药研发的坚强后盾作用。

围绕需求开展党建

“我们研究室的特点是学科专业性强、年轻党员多,同时高层次人才中党员比例较高。”张翱表示,要让支部工作与科研工作紧密结合,就必须得到课题组长、党员、职工群众的响应、支持和参与。

党总支主动与课题组长加强沟通,牵头组织3个党支部分别向所在课题组的组长和每位党员发出倡议信。张翱所说的两封信,一封是发给课题组长,恳请课题组把“难、急、苦”的科研项目交给党员干,委以重任,发挥作用;另一封是发给每位党员,以“金点子”形式,征求党员对支部建设的意见建议,集思广益,并落实到党员责任区。

“两份倡议书发出后,效果非常好,不仅得到了课题组长特别是非党员组长的理解和支持,也亮明了党员身份,让党员在科研方面起带头作用,作出承诺。”张翱表示,课题组长不仅在党员参与科研、参加支部活动的时间上给予了支持,还主动融入到党组织的活动中。

同时,为适应支部青年党员居多的特点,党总支运用电子媒介,在互联网上开通了“新药梦—药之源”总支博客,搭建线上学习交流平台。同时,设置“党建直通车”“药闻关注”“支部风采”等栏目,既为科研提供信息支撑,还引发党员思考。党总支还为每个课题组增设子栏目,加强了课题组间的联系。这种沟通交流方式使支部博客获得课题组长和党员的普遍欢迎。在两年的时间里,支部博客已发表80余篇博文,访问数达到近8800次,访问量年增长4000多次。

2013年以来,药化党总支相继被上海药物所党委授予学习型支部建设专项奖、网络党建优秀奖、学生党建特色奖、创新文化建设特色项目奖、红旗党总支等荣誉称号。

提升党员专业技能

从2014年至今,药化室转让的7个成果中有6个由党员团队完成。与2008年相比,党员在科研成果的取得中发挥了日益明显的作用。这一方面得益于药物所在承担国家“科技成果使用、处置和收益管理”改革试点的过程中收获了政策红利,另一方面也得益于该研究室长期的科研积累和党员骨干在科研业务上的突出表现。

来自沈竞康课题组的青年党员马宇驰,博士毕业后留在了药物所。2015年,他和团队研发的c-Met抑制剂成功转让给上海一家制药企业,金额达到1.1亿元。马宇驰表示,“这既是团队合作的结果,更得益于党组织、课题组给党员提供了很好的平台,使我们在科研工作中有了激情和热情。”

为让青年骨干不断增长“出新药”的本领,药化党总支搭建了集交流、展示和激励于一体的平台,并开设“支部学术沙龙”“药化青年论坛”。内容上不仅有药物研发新方法、新理念、新策略等与科研相关的主题报告,还有科研寄语、经验分享等。同时,不仅有所内外研究员以及新“百人”、新“***”登台交流,还有一线普通党员展示露面。

尽管只是学术报告,但党员们都不敢怠慢。各课题组长把组内参与同志作为展示本课题组研究实力的象征,通过组内筛选、党支部PK、党总支竞赛三个层面进行选拔,不仅历练了党员的科研和学术演讲水平,选树了一批优秀青年,也促进了党员发挥作用、参与党内活动的积极性。

上海药物所副所长、党委副书记、纪委书记厉骏表示,“活动不仅打开了课题组之间、研究室之间的交流大门,更为开展所际交流及更广泛的交流、开阔青年人视野、培养团队与合作精神开辟了通路。”

发挥党群组织作用

善于发挥群众组织作用也是药化党总支推进工作的有效方式。“我们不仅在每个课题组设立了党员联系人,还广泛调动、激发党外科研骨干参与党建工作的积极性,尝试开展了多项易于接受的工作项目,得到广大党员、非党课题组长和职工群众的普遍欢迎。”张翱表示。

在党总支、各支部的带动下,研究室工会、妇委大组、团支部纷纷行动起来,主动跟进,主动落实。2014年,根据该所“新药梦”部署,药化党总支组织了“党群共建共筑新药梦”主题活动。该活动由党总支策划,工会、团支部、妇委具体组织,12个课题组围绕新药精神讨论、文明室组特色活动、创新研究院建设与药物所发展等3个方面开展交流。

同时,近年来,该党总支在支部活动的内容、形式等方面作了新的尝试,形成了支部博客、新药沙龙、青年论坛等多个特色项目和品牌,“学习型、服务型、创新型”支部建设初显成效,极大地提升了支部的凝聚力和影响力,推动了新药研发源头的快速发展。

《中国科学报》 (2016-09-15 第4版 综合)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862548, encodeId=3e021862548c7, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Tue Mar 07 14:17:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811287, encodeId=3777181128e70, content=<a href='/topic/show?id=c20c8e69980' target=_blank style='color:#2F92EE;'>#药物化学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87699, encryptionId=c20c8e69980, topicName=药物化学)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Sep 22 16:17:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176001, encodeId=054c1e6001d7, content=见过他,种我老板关系好, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Mon Feb 13 22:34:01 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972161, encodeId=528f19e216135, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Oct 27 03:17:00 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299953, encodeId=2f88129995361, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 17 08:17:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
    2017-03-07 gous
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862548, encodeId=3e021862548c7, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Tue Mar 07 14:17:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811287, encodeId=3777181128e70, content=<a href='/topic/show?id=c20c8e69980' target=_blank style='color:#2F92EE;'>#药物化学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87699, encryptionId=c20c8e69980, topicName=药物化学)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Sep 22 16:17:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176001, encodeId=054c1e6001d7, content=见过他,种我老板关系好, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Mon Feb 13 22:34:01 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972161, encodeId=528f19e216135, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Oct 27 03:17:00 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299953, encodeId=2f88129995361, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 17 08:17:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862548, encodeId=3e021862548c7, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Tue Mar 07 14:17:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811287, encodeId=3777181128e70, content=<a href='/topic/show?id=c20c8e69980' target=_blank style='color:#2F92EE;'>#药物化学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87699, encryptionId=c20c8e69980, topicName=药物化学)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Sep 22 16:17:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176001, encodeId=054c1e6001d7, content=见过他,种我老板关系好, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Mon Feb 13 22:34:01 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972161, encodeId=528f19e216135, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Oct 27 03:17:00 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299953, encodeId=2f88129995361, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 17 08:17:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
    2017-02-13 wangyunyb

    见过他,种我老板关系好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1862548, encodeId=3e021862548c7, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Tue Mar 07 14:17:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811287, encodeId=3777181128e70, content=<a href='/topic/show?id=c20c8e69980' target=_blank style='color:#2F92EE;'>#药物化学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87699, encryptionId=c20c8e69980, topicName=药物化学)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Sep 22 16:17:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176001, encodeId=054c1e6001d7, content=见过他,种我老板关系好, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Mon Feb 13 22:34:01 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972161, encodeId=528f19e216135, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Oct 27 03:17:00 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299953, encodeId=2f88129995361, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 17 08:17:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1862548, encodeId=3e021862548c7, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Tue Mar 07 14:17:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811287, encodeId=3777181128e70, content=<a href='/topic/show?id=c20c8e69980' target=_blank style='color:#2F92EE;'>#药物化学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87699, encryptionId=c20c8e69980, topicName=药物化学)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Sep 22 16:17:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176001, encodeId=054c1e6001d7, content=见过他,种我老板关系好, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Mon Feb 13 22:34:01 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972161, encodeId=528f19e216135, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Oct 27 03:17:00 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299953, encodeId=2f88129995361, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 17 08:17:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
    2016-09-17 lqvr
Baidu
map
Baidu
map
Baidu
map